{
    "Trade/Device Name(s)": [
        "CR3 Keyless Split Sample Cup Amphetamine-Cocaine",
        "CR\u00b2 Keyless Split Sample Cup Amphetamine-Cocaine"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K141532",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130665"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DKZ",
        "DIO"
    ],
    "Summary Letter Date": "June 6, 2014",
    "Summary Letter Received Date": "June 10, 2014",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21CFR862.3100",
        "21CFR862.3250"
    ],
    "Regulation Name(s)": [
        "Amphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "d-Amphetamine",
        "Benzoylecgonine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [
        "Cup"
    ],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow"
    ],
    "Methodologies": [
        "Competitive binding",
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Specimen collection device",
        "Detection system"
    ],
    "Document Summary": "FDA 510(k) summary for CR3 Keyless Split Sample Cup Amphetamine-Cocaine rapid test for qualitative detection of amphetamine and cocaine metabolites in human urine",
    "Indications for Use Summary": "Rapid qualitative detection of d-Amphetamine and Benzoylecgonine (major metabolites of amphetamine and cocaine) in human urine at cutoffs of 1000 ng/mL and 300 ng/mL, for in vitro diagnostic, over-the-counter and prescription use",
    "fda_folder": "Toxicology"
}